Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease

2015-03-06

Inflammatory Bowel Diseases , Volume 21 - Issue 4 p. 951- 961

Additional Metadata
Keywords	biologic therapies, immunomodulators, inflammatory bowel disease, pediatric
Persistent URL	doi.org/10.1097/MIB.0000000000000245, hdl.handle.net/1765/88112
Journal	Inflammatory Bowel Diseases
Organisation	Department of Pediatrics
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Cozijnsen, M., Escher, J., Griffiths, A., Turner, D.& de Ridder, L. (2015). Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease. In Inflammatory Bowel Diseases (Vol. 21, Number 4, pp. 951–961).https://doi.org/10.1097/MIB.0000000000000245

Publication